Lassa fever: Vaccine candidate, Nigeria update
by News Desk from Outbreak News Today on (#4FQ1Z)
By NewsDesk @bactiman63 Lassa Fever Candidate Vaccine Inovio Pharmaceuticals, Inc. announced Tuesday announced it has dosed subjects in a Phase 1, first-in-human clinical trial to evaluate INO-4500, its DNA candidate vaccine to prevent infection from the Lassa virus. Inovio plans to enroll approximately 60 volunteers in this placebo controlled, blinded, dose escalation study evaluating INO-4500 ["]
The post Lassa fever: Vaccine candidate, Nigeria update appeared first on Outbreak News Today.